That hypothesis is supported by the finding that an NGF metabolic dysregulation is indeed present in the AD pathology even at preclinical stages as demonstrated in the analysis of post-mortem brain tissue, plasma, and CSF [96,98,100,104,105,106]. Here, NGF is linked to Alzheimer disease.